FoxHollow Announces Marketing and Sales Management Transitions; Names Experienced Healthcare Industry Consultant as Vice Preside
January 08 2007 - 8:20AM
PR Newswire (US)
REDWOOD CITY, Calif., Jan. 8 /PRNewswire-FirstCall/ -- FoxHollow
Technologies (NASDAQ:FOXH), which manufactures and markets
minimally invasive devices for the treatment of peripheral artery
disease (PAD), today announced changes within its marketing and
sales organizations. The company said that Michael P. Ennen, M.D.
has joined as vice president, global marketing. Ennen spent the
past five years in the healthcare practice of the consulting firm
of McKinsey & Company, where he provided strategic and
marketing counsel for medical device, pharmaceutical and
biotechnology companies. Before that, Ennen was associated with the
investment banking firm of Goldman Sachs and the medical
development office of Stanford University. He holds a B.S. in
Genetics and Ecology from the University of Minnesota and a Doctor
of Medicine from the Stanford University School of Medicine. "We
are delighted to have someone with Mike's deep medical background
and industry knowledge joining FoxHollow," noted Duke Rohlen,
president of strategic operations. "He brings a broad range of
experience working with healthcare companies to develop and
implement commercialization and product development strategies.
Mike is entering this position with a deep understanding of the PAD
market and an appreciation of the company's potential for continued
growth," Rohlen continued. In addition, FoxHollow announced that
Richard Zimmer, senior vice president of sales, will be leaving the
company at the end of the first quarter of 2007. The company has
initiated a search for his replacement. Both the company's sales
and marketing organizations will now report to Rohlen. "Richard
will be missed by the entire community of FoxHollow employees and
physicians," commented John Simpson, Ph.D., M.D., the company's
chief executive officer. "His dedication to his team, customers and
patients suffering from PAD is unrivaled. He deserves the utmost
respect and appreciation for his accomplishments during more than
three years with the company. We wish him the very best in his
future endeavors." About FoxHollow Technologies FoxHollow
Technologies, Inc., develops and markets minimally invasive devices
for the removal of plaque and thrombus for the treatment of
peripheral artery disease (PAD). PAD results from plaque that
accumulates in the arteries and blocks blood flow in the legs.
These blockages can result in severe pain for patients and very
limited physical mobility. The company's SilverHawk Plaque Excision
System is a minimally invasive method of removing the obstructive
plaque and restoring blood flow to the legs and feet. The company's
Rinspirator thrombectomy system removes thrombus, or blood clots,
from occluded arteries in patients suffering from PAD or coronary
artery disease (CAD). For more information, please visit our
website at http://www.foxhollowtech.com/. Forward-Looking
Statements This press release contains forward-looking statements
within the meaning of the U.S. Private Securities Litigation Reform
Act of 1995. Statements in this press release regarding FoxHollow's
businesses that are not historical fasts may be "forward-looking
statements" that involve risks and uncertainties. Specifically,
statements regarding the company's growth strategies and potential
are forward-looking statements involving risks and uncertainties.
Forward-looking statements are base on management's current,
preliminary expectations, and are subject to risks and
uncertainties that could cause actual results to differ from the
results predicted. These risks and uncertainties are included under
the caption, "Factors Affecting Future Operating Results," in
"Management's Discussion and Analysis of Financial Condition and
Results of Operations," in our most recent quarterly report on Form
10-Q for the quarter ended September 30, 2006, filed with the SEC
on November 9, 2006, and available on our investor relations
website at http://www.foxhollowtech.com/ and on the SEC's website
at http://www.sec.gov/. Undue reliance should not be placed on
forward-looking statements, which speak only as of the date they
are made. FoxHollow undertakes no obligation to update publicly any
forward-looking statements to reflect new information, events or
circumstances after the date they were made, or to reflect the
occurrence of unanticipated events. Contacts: Matt Ferguson Chief
Financial Officer 650-421-8449 Robin Gaffney Media Relations
650-421-8614 DATASOURCE: FoxHollow Technologies, Inc. CONTACT: Matt
Ferguson, Chief Financial Officer, +1-650-421-8449, or , or Robin
Gaffney, Media Relations, +1-650-421-8614 or , both of FoxHollow
Technologies, Inc. Web site: http://www.foxhollowtech.com/
Copyright
Foxhollow (NASDAQ:FOXH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Foxhollow (NASDAQ:FOXH)
Historical Stock Chart
From Jul 2023 to Jul 2024